FREDERICK, Md., Feb. 4, 2015 /PRNewswire/ -- BioElectronics
Corporation (OTC Pink: BIEL), the maker of advanced drug-free
consumer medical devices, today released analysis of its ongoing
and second long term follow up survey of customers in the
United Kingdom and Ireland who are managing chronic pain with
ActiPatch® Therapy, and reducing their dependence on systemic pain
drugs. The study of more than 1,300 consumers looked at their
chronic pain management, quality of life, pain medication use, and
purchasing extent of ActiPatch®.
"The consumer responses confirm that ActiPatch® Therapy is a
well-accepted chronic pain therapy that has a significant and
meaningful impact on the user's severe chronic pain levels and
quality of life," said Ian Rawe,
Ph.D., Director of Clinical Research at BioElectronics
Corporation. "One important aspect of this level of pain
reduction is that a majority of ActiPatch® users are reporting a
marked decrease in systemic analgesic pain medication use including
reductions in opioid based analgesics."
Overall, the follow up survey found that ActiPatch® is being
well accepted and that a high percent of consumers who have used
the 7- Day ActiPatch® sample are moving onto a purchase of the
commercial ActiPatch® device.
Key user findings:
- 90% reported long lasting 50% pain reduction.
- 85% indicated a moderate to great improvement of their quality
of life.
- 85% indicated reduction in the use of pain medications.
- Of those taking opioids pain drugs alone, 76% reported a
moderate to complete elimination of their use.
ActiPatch® Therapy devices are readily available
over-the-counter outside of the US for approximately $30.00 retail, or $0.04 per hour of therapy. Visit
www.bielcorp.com/clinical-evidence/musculoskeletal-pain to see more
detailed consumer responses and www.facebook.com/ActiPatch to view
what people in the UK and Ireland
are saying about the products.
About BioElectronics Corporation
BioElectronics
Corporation is a leader in Bioelectronics and the maker of a family
of disposable, drug-free, medical devices: ActiPatch®
Therapy, over-the-counter treatment for back pain and other
musculoskeletal complaints; RecoveryRx® Devices for
chronic and post-operative wound care; Allay® Menstrual
Pain Therapy; and HealFast® Therapy for dogs, cats and
horses. For more information, please visit
www.bielcorp.com.
Contact: Paul Knopick:
940.262.3584
pknopick@eandecommunications.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bioelectronics-actipatch-actual-use-survey-finds-90-have-excellent-chronic-pain-management-and-88-had-a-decrease-in-opioid-use-300030551.html
SOURCE BioElectronics Corporation